Post-RAI Therapy Dosimetry and Quality Assessment of Target Tissue Dosing
Launched by STATE UNIVERSITY OF NEW YORK - UPSTATE MEDICAL UNIVERSITY · Aug 31, 2023
Trial Information
Current as of June 27, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
In our current clinical practice, patients with well-differentiated thyroid cancer (DTC) who receive oral administration of radioiodine 1-131 (RAI) have whole body and planar images obtained 4-5 days post-treatment. These images often do not adequately depict residual iodine-avid disease in the thyroid bed, neck or mediastinum. Further, no information about what dose taken up by the tumor remnant is obtained and thus we are unable to know how much radionuclide actually went to the residual disease/tissue.
Using single photon emission computed tomography (SPECT)/CT we will be able to better...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All minorities
- • 18 years of age and older
- • Ability to give consent
- • Male or female
- • Differentiated thyroid cancer (DTC)
- • Previous total thyroidectomy
- * Has either:
- • local lymph node metastases
- • distant mediastinal/cervical metastases
- • lung or osseous metastases as seen on prior imaging studies
- Exclusion Criteria:
- • Non-iodine avid disease
- • Under 18 years of age
- • Unable to give consent
- • Pregnant women, Non-viable neonates or neonates of uncertain viability.
- • Non-English-speaking patients
About State University Of New York Upstate Medical University
The State University of New York - Upstate Medical University is a premier academic institution dedicated to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, Upstate Medical University focuses on translating scientific discoveries into effective medical treatments and improving patient outcomes. With a commitment to excellence in clinical research, the university collaborates with multidisciplinary teams to conduct studies that address critical health challenges, ensuring rigorous methodologies and adherence to ethical standards. Through its robust infrastructure and expertise, Upstate Medical University plays a vital role in shaping the future of medicine and enhancing community health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Syracuse, New York, United States
Patients applied
Trial Officials
David Lubin, MD, PhD
Principal Investigator
State University of New York - Upstate Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported